Arcutis Biotherapeutics, Inc. (ARQT) stock
ARQTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/30368% above fair value
$28.26+0.73 (+2.65%)
Close on Nov 13, 2026Market cap $3.55BP/E 128.5Yield –
Arcutis Biotherapeutics total assets
Total assets on the balance sheet at the end of each period.
Arcutis Biotherapeutics's total assets was $524.43M at Sep 30, 2026. For fiscal 2025 it was $432.97M, up 24.1% from the year before. The highest annual figure on record is $449.27M in fiscal 2022.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $432.97M | +24.1% |
| FY2024 | Dec 31, 2024 | $348.89M | +2.2% |
| FY2023 | Dec 31, 2023 | $341.37M | -24.0% |
| FY2022 | Dec 31, 2022 | $449.27M | +10.1% |
| FY2021 | Dec 31, 2021 | $408.15M | +36.8% |
| FY2020 | Dec 31, 2020 | $298.27M | +178.7% |
| FY2019 | Dec 31, 2019 | $107.01M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $524.43M | +41.4% |
| Q2 FY2026 | Jun 30, 2026 | $488.54M | +38.6% |
| Q1 FY2026 | Mar 31, 2026 | $460.00M | +33.7% |
| Q4 FY2025 | Dec 31, 2025 | $432.97M | +24.1% |
| Q3 FY2025 | Sep 30, 2025 | $370.98M | -15.2% |
| Q2 FY2025 | Jun 30, 2025 | $352.43M | -20.8% |
| Q1 FY2025 | Mar 31, 2025 | $344.11M | -28.1% |
| Q4 FY2024 | Dec 31, 2024 | $348.89M | +2.2% |
| Q3 FY2024 | Sep 30, 2024 | $437.35M | +49.3% |
| Q2 FY2024 | Jun 30, 2024 | $444.76M | +38.7% |
| Q1 FY2024 | Mar 31, 2024 | $478.54M | +26.1% |
| Q4 FY2023 | Dec 31, 2023 | $341.37M | -24.0% |
| Q3 FY2023 | Sep 30, 2023 | $292.96M | -42.4% |
| Q2 FY2023 | Jun 30, 2023 | $320.69M | +6.7% |
| Q1 FY2023 | Mar 31, 2023 | $379.46M | +4.2% |
| Q4 FY2022 | Dec 31, 2022 | $449.27M | +10.1% |
| Q3 FY2022 | Sep 30, 2022 | $508.91M | +31.5% |
| Q2 FY2022 | Jun 30, 2022 | $300.46M | -30.6% |
| Q1 FY2022 | Mar 31, 2022 | $364.11M | -22.8% |
| Q4 FY2021 | Dec 31, 2021 | $408.15M | +36.8% |
| Q3 FY2021 | Sep 30, 2021 | $387.01M | +95.4% |
| Q2 FY2021 | Jun 30, 2021 | $432.89M | +86.6% |
| Q1 FY2021 | Mar 31, 2021 | $471.42M | +85.3% |
| Q4 FY2020 | Dec 31, 2020 | $298.27M | +178.7% |
| Q3 FY2020 | Sep 30, 2020 | $198.01M | – |
| Q2 FY2020 | Jun 30, 2020 | $231.97M | – |
| Q1 FY2020 | Mar 31, 2020 | $254.39M | – |
| Q4 FY2019 | Dec 31, 2019 | $107.01M | – |
See a number that looks wrong?